(FTRE) Fortrea Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US34965K1079

Clinical Trials, Development Consulting, Pharmacology Services, Trial Management

Stock: Life Sciences Tools & Services
Age 2.6y

MCap 1,603m
Avg Vol 1.23M (21.0M USD)

Beta 1.895
Volatility 76.25%

EPS (Earnings per Share)

EPS CAGR: -41.27%
EPS Trend: -48.0%

Last SUE: -0.25
Qual. Beats: 0

Revenue

Rev. CAGR: -2.96%
Rev. Trend: -16.8%

Last SUE: 0.62
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	76.3%
Value at Risk 5%th	114%
Relative Tail Risk	-9.11%

Reward TTM
Sharpe Ratio	0.37
Alpha	-32.19
CAGR/Max DD	-0.22

Character TTM
Hurst Exponent	0.525
Beta	1.895
Beta Downside	2.463

Drawdowns 3y
Max DD	89.92%
Mean DD	45.99%
Median DD	48.25%

Description: FTRE Fortrea Holdings January 26, 2026

Fortrea Holdings Inc. (NASDAQ:FTRE) is a contract research organization that delivers end-to-end development and consulting services for biopharmaceutical products and medical devices, spanning Phase I-IV clinical trials, clinical pharmacology, and hybrid delivery models such as full-service and functional-service provider structures.

Key recent metrics show the company generated $45 million of revenue in Q4 2025, maintains a cash runway of roughly $120 million, and reports a contract backlog of about $200 million, indicating strong demand for its specialized testing services, including the lot-by-lot MNP impurity assay for rifampin in collaboration with Emery Pharma.

The CRO sector is benefitting from a projected 6% CAGR through 2030, driven by accelerated timelines for advanced-therapy development and increasing regulatory emphasis on drug-drug interaction safety-trends that directly support Fortrea’s strategic partnership with SCT Cell Manufacturing to speed advanced-therapy pipelines.

For a deeper, data-driven view of Fortrea’s valuation dynamics, consider exploring the company’s profile on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income: -1.01b TTM > 0 and > 6% of Revenue
FCF/TA: -0.00 > 0.02 and ΔFCF/TA -6.48 > 1.0
NWC/Revenue: 0.15% < 20% (prev 5.09%; Δ -4.94% < -1%)
CFO/TA 0.00 > 3% & CFO 1.50m > Net Income -1.01b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.00 > 1.5 & < 3
Outstanding Shares: last quarter (91.2m) vs 12m ago 1.33% < -2%
Gross Margin: 17.19% > 18% (prev 0.18%; Δ 1700 % > 0.5%)
Asset Turnover: 86.17% > 50% (prev 75.74%; Δ 10.43% > 0%)
Interest Coverage Ratio: -10.36 > 6 (EBITDA TTM -852.8m / Interest Expense TTM 90.0m)

Altman Z'' -4.29

A: 0.00 (Total Current Assets 918.5m - Total Current Liabilities 914.4m) / Total Assets 2.74b
B: -0.49 (Retained Earnings -1.35b / Total Assets 2.74b)
C: -0.29 (EBIT TTM -932.3m / Avg Total Assets 3.20b)
D: -0.70 (Book Value of Equity -1.52b / Total Liabilities 2.16b)
Altman-Z'' Score: -4.29 = D

Beneish M -3.44

DSRI: 0.97 (Receivables 663.2m/689.1m, Revenue 2.76b/2.77b)
GMI: 1.08 (GM 17.19% / 18.49%)
AQI: 0.88 (AQ_t 0.61 / AQ_t-1 0.70)
SGI: 0.99 (Revenue 2.76b / 2.77b)
TATA: -0.37 (NI -1.01b - CFO 1.50m) / TA 2.74b)
Beneish M-Score: -3.44 (Cap -4..+1) = AA

ValueRay F-Score (Strict, 0-100) 29.12

1. Piotroski: 2.50pt
2. FCF Yield: -0.49%
3. FCF Margin: -0.47%
4. Debt/Equity: 2.04
5. Debt/Ebitda: data missing
6. ROIC - WACC: -44.73%
7. RoE: -119.7%
8. Revenue Trend: -16.83%
9. EPS Trend: -47.98%

What is the price of FTRE shares?

As of January 27, 2026, the stock is trading at USD 17.06 with a total of 882,197 shares traded.
Over the past week, the price has changed by +7.84%, over one month by -1.95%, over three months by +64.20% and over the past year by -4.48%.

Is FTRE a buy, sell or hold?

Fortrea Holdings has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold FTRE.

Strong Buy: 0
Buy: 1
Hold: 10
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the FTRE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	16.4	-3.6%
Analysts Target Price	16.4	-3.6%
ValueRay Target Price	17.9	4.8%

FTRE Fundamental Data Overview January 24, 2026

P/E Forward = 19.084
P/S = 0.5809
P/B = 2.7634
P/EG = 1.1783
Revenue TTM = 2.76b USD
EBIT TTM = -932.3m USD
EBITDA TTM = -852.8m USD
Long Term Debt = 1.05b USD (from longTermDebt, last quarter)
Short Term Debt = 83.7m USD (from shortTermDebt, last quarter)
Debt = 1.19b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.06b USD (from netDebt column, last quarter)
Enterprise Value = 2.66b USD (1.60b + Debt 1.19b - CCE 131.3m)
Interest Coverage Ratio = -10.36 (Ebit TTM -932.3m / Interest Expense TTM 90.0m)
EV/FCF = -204.5x (Enterprise Value 2.66b / FCF TTM -13.0m)
FCF Yield = -0.49% (FCF TTM -13.0m / Enterprise Value 2.66b)
FCF Margin = -0.47% (FCF TTM -13.0m / Revenue TTM 2.76b)
Net Margin = -36.77% (Net Income TTM -1.01b / Revenue TTM 2.76b)
Gross Margin = 17.19% ((Revenue TTM 2.76b - Cost of Revenue TTM 2.29b) / Revenue TTM)
Gross Margin QoQ = 14.70% (prev 16.04%)
Tobins Q-Ratio = 0.97 (Enterprise Value 2.66b / Total Assets 2.74b)
Interest Expense / Debt = 1.90% (Interest Expense 22.6m / Debt 1.19b)
Taxrate = 21.0% (US default 21%)
NOPAT = -736.5m (EBIT -932.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.00 (Total Current Assets 918.5m / Total Current Liabilities 914.4m)
Debt / Equity = 2.04 (Debt 1.19b / totalStockholderEquity, last quarter 580.8m)
Debt / EBITDA = -1.24 (negative EBITDA) (Net Debt 1.06b / EBITDA -852.8m)
Debt / FCF = -81.23 (negative FCF - burning cash) (Net Debt 1.06b / FCF TTM -13.0m)
Total Stockholder Equity = 847.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.69% (Net Income -1.01b / Total Assets 2.74b)
RoE = -119.7% (Net Income TTM -1.01b / Total Stockholder Equity 847.8m)
RoCE = -49.07% (EBIT -932.3m / Capital Employed (Equity 847.8m + L.T.Debt 1.05b))
RoIC = -36.68% (negative operating profit) (NOPAT -736.5m / Invested Capital 2.01b)
WACC = 8.05% (E(1.60b)/V(2.79b) * Re(12.90%) + D(1.19b)/V(2.79b) * Rd(1.90%) * (1-Tc(0.21)))
Discount Rate = 12.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.91%
Fair Price DCF = unknown (Cash Flow -13.0m)
EPS Correlation: -47.98 | EPS CAGR: -41.27% | SUE: -0.25 | # QB: 0
Revenue Correlation: -16.83 | Revenue CAGR: -2.96% | SUE: 0.62 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.14 | Chg30d=+0.005 | Revisions Net=+4 | Analysts=10
EPS next Year (2026-12-31): EPS=0.78 | Chg30d=-0.002 | Revisions Net=+2 | Growth EPS=+53.6% | Growth Revenue=+0.2%

Additional Sources for FTRE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle